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Abstract
Background: Zidovudine (AZT) constitutes part of the recommended regimens for prevention and treatment of HIV-1
infection. At the same time, AZT as well as HIV-1 infection itself may induce mitochondrial damage. In this study, we
analyzed the impact of prenatal AZT-exposure on mitochondrial alterations in HIV-infected women and their infants.
Methods: Mitochondrial DNA (mtDNA) levels in placentas of HIV-1 infected Tanzanian women with and without prenatal
AZT exposure, and in the umbilical cords of their AZT-exposed/unexposed infants were quantified using real-time PCR.
Furthermore, we checked for the most common mitochondrial deletion in humans, the 4977 base pair deletion
(dmtDNA4977) as a marker for mitochondrial stress.
Results: 83 women fulfilled the inclusion criteria. 30 women had been treated with AZT (median duration 56 days; IQR 43–
70 days) while 53 women had not taken AZT during pregnancy. Baseline maternal characteristics in the two groups were
similar. The median mtDNA levels in placentas and umbilical cords of women (311 copies/cell) and infants (190 copies/cell)
exposed to AZT were significantly higher than in AZT-unexposed women (187 copies/cell; p = 0.021) and infants (127
copies/cell; p = 0.037). The dmtDNA4977 was found in placentas of one woman of each group and in 3 umbilical cords of
AZT-unexposed infants but not in umbilical cords of AZT-exposed infants.
Conclusions: Antenatal AZT intake did not increase the risk for the common mitochondrial deletion dmtDNA4977. Our data
suggests that AZT exposure elevates mtDNA levels in placentas and umbilical cords possibly by positively influencing the
course of maternal HIV-1 infection.
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Introduction
HIV-positive pregnant women can decrease the risk for in-utero
vertical HIV transmission by intake of antiretroviral drugs (ARVs).
Zidovudine (AZT) during pregnancy is a frequently used and
WHO- recommended drug regimen [1]. However, it has been
proven in human and animal studies that Nucleoside Reverse
Transcriptase Inhibitors (NRTIs) like AZT can cause mitochon-
drial damages including depletion of mitochondrial DNA
(mtDNA) [2–10].
One underlying mechanism of AZT-induced mitochondrial
toxicity is the inhibition of human DNA polymerase gamma [11–
12], the enzyme needed for replication of mtDNA. Other assumed
mechanisms include increased mitochondrial oxidative stress,
introduction of mtDNA mutations, negative effects on nucleotide
phosphorylation and mitochondrial gene expression, depletion of
L-carnitine and inhibition of the mitochondrial bioenergetic
machinery [13–17].
However, also HIV-1 infection itself causes mitochondrial
damage, like depletion of mtDNA and decreased activities of the
mitochondrial respiratory chain complexes [18–21]. HIV-1 has
been shown to induce mitochondrial toxicity in several ways: by
loss of mitochondrial membrane potential, by increase of reactive
oxygen species and through different mechanisms of the viral
proteins Vpr, Tat and HIV protease [22].
In humans, the mitochondrial toxicity of antenatal NRTI-
exposure was determined by measuring different mitochondrial
parameters like the emergence of clinical mitochondriopathy or
death [23–25], quantification of mtDNA [18,26–29], analysis of
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mtDNA mutations [30] or expression of mitochondrial respiratory
chain proteins [27].
Studies indicating NRTI-induced mitochondrial toxicity include
a detailed analysis by Barret [23], who found a higher incidence of
neuro-mitochondrial diseases in NRTI-exposed infants compared
to NRTI-unexposed infants; Divi [28] found a decrease of mtDNA
in umbilical cords of infants of HIV-positive mothers exposed to
Combivir compared to infants of HIV-negative women. Shir-
amizu [26] measured lower mtDNA contents in placenta and cord
blood of HIV-positive women following NRTI-exposure in
comparison to HIV-negative individuals. Torres [30] detected
a higher frequency of mtDNA mutations in umbilical cords of
HIV-positive AZT exposed infants compared to HIV-negative
infants.
In contrast, McComsey [27] identified increased mtDNA levels
without changes in expression of mitochondrial respiratory chain
proteins in infants of HIV-positive mothers having taken NRTIs
compared to NRTI-unexposed infants of HIV-negative mothers.
Williams [31] did not detect lower mental or motor functioning
scores in HIV-exposed, uninfected infants who were in-utero
exposed to ARVs including NRTIs compared to those unexposed
to ARVs during pregnancy. Accordingly, two large cohort studies
did not discover an increased risk for death or clinical
manifestations suggestive of mitochondrial abnormalities in
NRTI-exposed infants [24–25].
The only two studies comparing mtDNA levels exclusively
among HIV-positive mothers and their infants came to contra-
dictory conclusions. In blood samples of HIV-positive mothers and
infants with and without prenatal AZT exposure, Poirier [29]
found lower mtDNA levels in AZT-exposed infants, whereas
Aldrovandi [18] identified higher mtDNA levels in women and
newborns with antenatal AZT exposure.
Altogether, it has not been clarified whether the net effect of
short-course AZT for drug-naive HIV-1 infected pregnant women
and their infants is a positive or a negative one with regard to
mitochondriopathy. In the present study, we therefore quantified
the mtDNA content in placentas of HIV-1 positive women with
and without antenatal AZT exposure and in umbilical cords of
their AZT exposed/unexposed infants. Furthermore, we checked
for the most common mitochondrial deletion in humans, the 4977




Ethical approval was obtained from the local Mbeya Medical
Research and Ethics Committee, the National Institute for
Medical Research of Tanzania and the ethical committee of
Charitè-Universitätsmedizin Berlin, Germany. All participants
had given written informed consent, and data and samples were
treated strictly confidentially.
Clinical Samples
The present study is a sub-evaluation of an observational study
analyzing feasibility and adherence regarding combination pro-
phylaxis for the prevention of mother-to-child transmission of
HIV-1 (PMTCT) at Kyela District Hospital (KDH), Mbeya
Region, Tanzania between October 2008 and September 2009
[33].
According to the WHO guidelines from 2006 and the National
Tanzanian PMTCT guidelines from 2007 [34–35], HIV-1
positive women without treatment indication (CD4 cell count
.200 cells/ml) took AZT, starting in gestational week 28
(26300 mg per day), or anytime thereafter followed by single-
dosed Nevirapine (200 mg) at labor onset and AZT (300 mg)
every three hours, plus Lamivudine (150 mg) every 12 hours
during labor; additionally, the mother took postnatal AZT/
Lamivudine for one week. Newborns received single-dosed
Nevirapine after birth and AZT for 1 week [33].
PMTCT clients who had taken antenatal AZT for at least
4 weeks and who delivered at KDH within the study period were
eligible for this sub-study if placenta and/or umbilical cord
specimens were available, if the mother delivered a singleton, and
if both mother and infant were alive 48 hours after birth. The
same eligibility criteria applied for HIV-1 positive women
delivering at KDH who had not taken AZT during pregnancy,
constituting the control group. These women were offered the
same intrapartum and postpartum drug regimen as described
above. Since the half-life of mtDNA in mammalian cells is several
days [36], ARV exposure during labor and thus shortly before the
samples were taken should not affect mtDNA levels and the
presence of the dmtDNA4977 deletion. Aliquots of placenta and
umbilical cords of HIV-1 positive women and their infants were
sampled at delivery, frozen and stored at 220uC for future DNA
extraction. For the detection and quantification of HIV-1 RNA
viral load in newborns, a plasma sample from delivery was used
and analyzed by RT-PCR according to our previously published
protocol [37]. Socio-demographic data, AZT intake and maternal
and newborn parameters were documented using specific ques-
tionnaires during antenatal care and at delivery [33].
Quantification of Mitochondrial DNA and the
Mitochondrial 4977 bp Deletion (dmtDNA4977)
DNA extraction. 50 mg of each tissue (placenta and umbil-
ical cord) were subjected to DNA extraction using the Invisorb
Spin tissue mini kit. Samples were incubated at 52uC overnight
and vortexed in an Invisorb Gyrator to intensify the lysis process
(both STRATEC Molecular, former Invitek, Berlin, Germany).
DNA was eluted in 55 ml elution buffer and stored at 4uC or
analyzed immediately by PCR.
Real-time PCR for absolute quantification of nuclear
DNA. Nuclear DNA was quantified as previously described [38].
Briefly, a 98 bp fragment of the telomerase gene (forward primer:
59-GGC ACA CGT GGC TTT TCG-39, reverse primer: 59-
GGT GAA CCT CGT AAG TTT ATG CAA-39) was used to
specifically amplify nuclear DNA. Dilutions of control DNA
(Promega, Mannheim, Germany) were prepared (100 ng, 10 ng,
2.5 ng, 1.0 ng, 0.5 ng, 0.1 per ml) and used as standards assuming
approximately 1,500 haploid copies of the telomerase gene in
10 ng total control DNA [39]. Every sample was amplified in
triplets using 2 ml of pure DNA extract. The thermal cycling
program was: 10 s at 50uC and 10 min at 95uC for enzyme
activation (allowing an automated hot start PCR), 40 cycles of
denaturation for 30 s at 94uC and 60 s annealing at 65uC on an
ABI 7300 Real Time PCR System (Applied Biosystems). This
approach allowed calculation of the amount of DNA/ml in ng and
the number of cells/ml.
Real-time PCR for absolute quantification of
mitochondrial DNA. Absolute quantification of dmtDNA4977
and total mtDNA was done as presented in [40] with some
changes. To test the precision and reliability of the real time PCR,
the primer pair L15/H16 (np: L3304-L3328/H3564-H3539 in
[41] was employed to produce synthetic ND1 targets of 260 bp in
length, which were used as specific template molecules for
undeleted wildtype mtDNA in the subsequent PCRs. These
ND1 targets were purified from primer sequences by ultrafiltration
through Centricon 30 membranes and quantified after gel
mtDNA in Placenta and Umbilical Cord
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electrophoresis and detection on a gel imaging system (Geldoc,
Biorad). Then, the molecules were serially ten-fold diluted from
106 to 1 copies/10 ml, and mixed with 100 ng mouse DNA
(15,000 haploid genome equivalents) per 10 ml each to simulate
the complexity of the human genome.
For quantification of dmtDNA4977, a 238-bp fragment was
amplified using the primer pair L35/H45 (np: L8285-L8310/
H13499-H13475, [41]). These primers flank the breakpoints of the
common deletion and preferentially amplify dmtDNA4977 under
short cycle conditions. Known numbers of the purified 238-bp
products served as targets for quantification of specifically deleted
molecules in our DNA samples. The standard preparation was
done in the same way as described for total mtDNA. For detection
of specific PCR products, we used FAM-labeled probes for
wildtype and VIC-labeled probes for dmtDNA4977. For sample
analysis, a real time duplex-PCR was performed using standard
mixtures of 1, 10, 100 and 1000 dmtDNA4977 specific fragments
on a background of 106 wildtype specific template molecules.
Each amplification was done in triplets. PCR was performed using
a standard Immuno buffer and an Immolase polymerase at
a concentration of 1 U/25 ml per reaction (both Bioline
Germany). The concentrations of the primers, magnesium
chloride, and dNTPs were 0.0002 mM, 1.5 mM, and 0.2 mM
per dNTP, respectively. Dimethylsulfooxide (DMSO, SIGMA,
Steinheim, Germany) was added as an additive in a concentration
of 2%.
Statistical Analysis
For statistical analysis, the non-parametric Mann-Whitney U
test was used to assess significant differences with regard to
continuous variables between two independent samples whereas
the Chi-Square test or Fisher’s exact test were applied to analyze
the independence of categorical variables. Testing of significant
correlations between two continuous variables was done by
Pearson’s correlation coefficient. Levels of mtDNA in placenta
and umbilical cord were logarithmically transformed and pre-
sented as box and whisker plots. For descriptive analysis, median
and interquartile ranges (IQR) were calculated. Two-sided tests
were used and P,0.05 was considered as statistically significant.
Statistical analysis was carried out using PASW Statistics 18 (SPSS
Inc., Chicago, Illinois, USA).
Results
Sample Characteristics
In total, 83 women and their infants fulfilled the inclusion
criteria. Samples of 30 women having taken AZT antenatally for
a median duration of 56 days (IQR 43–70 days) and their infants
were compared with samples of 53 women without pre-delivery
AZT exposure and their infants. No significant differences
between the two groups could be observed with regard to
maternal CD4 cell count or socio-demographic variables like age,
weight, education or marital status of the mother or infant’s birth
weight and length (table 1).
The proportion of HIV-1 infected newborns at birth was similar
in the two groups; 4/44 AZT-unexposed infants versus 2/30 AZT-
exposed infants (p = 1.0). Since the exclusion of data of HIV-1
infected infants did not change the results (data not shown) we
decided to keep the data of HIV-infected infants in the analysis.
Levels of mtDNA in Placenta and Umbilical Cord
The median mtDNA level was significantly higher in women
exposed to AZT (311 copies per cell, IQR 166–475) compared to
women without AZT-exposure (187 copies per cell, IQR 115–352;
p = 0.021). Accordingly, the median mtDNA level was significantly
higher in umbilical cords of infants exposed to AZT (190 copies
per cell, IQR 121–323) compared to infants without AZT-
exposure (127 copies per cell, IQR 70–234; p = 0.037). The box
and whisker plots of mtDNA levels in placentas of HIV-1 infected
women and in umbilical cords of their infants according to
antenatal AZT-exposure are shown in figure 1. Restricting the
analysis to women having taken AZT during pregnancy, we did
not find a correlation between the duration of antenatal AZT
intake in days and mtDNA levels in placenta (p = 0.95) and
umbilical cord (p = 0.76).
Frequency of dmtDNA4977 in Placenta and Umbilical
Cord
The mitochondrial 4977-bp deletion was rarely found in
placental tissues (1/43 AZT- unexposed women versus 1/24
AZT-exposed women, p = 1.0). These two women displayed the
mtDNA4977 at very low proportions with mutant DNA in
percentage of the total DNA being 2.6E-05 (woman unexposed to
AZT and 2.9E-05 (woman exposed to AZT).
In umbilical cords of infants, the dmtDNA4977 was detectable
in 3/47 (6.4%) infants without AZT exposure and in no infant
with prenatal AZT exposure (0/23); this was not statistically
different (p = 0.55). The proportion of mutant DNA in percentage
was higher in umbilical cords than in the placental tissues: 9.4E-
04, 6.9E-03 and 1.4E-02.
In no case, the dmtDNA4977 was detected in both placenta and
umbilical cord of a mother-child-pair.
Discussion
There is a high level of evidence from animal and human
studies that both AZT and HIV-1 can cause mitochondrial
toxicity and reduce mtDNA levels [2–10,18–22].
As a main finding, our study detected higher mtDNA levels in
AZT-exposed mother-child- pairs compared to unexposed ones.
This is in accordance with findings by Aldrovandi [18], who
analyzed samples of HIV-positive mothers with similar HIV-1
disease progression but differing antenatal exposure towards
NRTIs; higher mtDNA levels in the AZT-exposed mother-infant
group were detected even five years later. Contradictingly, Poirier
et al. [29] achieved results indicating lower mtDNA levels in the
AZT-exposed infants. Yet, this study is only partly comparable
because both infant groups differed remarkably in the HIV-1
disease progression of their mothers, with those having taken AZT
displaying a tenfold higher viral load and .twofold lower CD4 cell
count levels [29].
We analyzed mtDNA levels in placentas and umbilical cords
instead of PBMCs. While mtDNA levels in PBMCs do not
necessarily correlate with mtDNA levels in other tissues or with
clinical signs of mitochondriopathy [42–44], placentas and
umbilical cords seem to reflect mitochondrial changes induced
by AZT: antenatal AZT–exposure led to decreased mtDNA levels
in placentas and umbilical cords of fetal patas monkeys, which was
correlated with an increase in mitochondrial morphological
changes [6,9]. This suggests that mtDNA levels in placenta and
umbilical cord reflect mitochondrial damage and are thus suitable
markers of potential mitochondrial toxicity following AZT-
exposure.
To our knowledge, this study is the first to analyze the presence
and the relative amount of dmtDNA4977, the most common
mitochondrial mutation, in placentas of HIV-infected women and
umbilical cords of their infants with and without exposure to
ARVs. In our study, dmtDNA4977 detection was rare and could
mtDNA in Placenta and Umbilical Cord
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only be detected in placentas of a single AZT-exposed and AZT-
unexposed woman each, at very low proportions. This finding is
consistent with other studies [45–46] which did not find the
dmtDNA4977 in human placenta samples.
The occurence of mtDNA4977 has been shown to be age-
dependent and was undetectable in tissue biopsies of children [47–
48]. However, the deletion has been identified in brain, liver,
kidney, heart, and muscle samples taken at autopsy of deceased
neonates [49]. The authors speculate that mtDNA4977 could be
generated by perinatal hypoxia or temporary oxygen oversatura-
tions during the intensive care of the neonates.
Here, we demonstrate that mtDNA4977 can also be observed in
newborns of HIV-1 infected women. We identified the
dmtDNA4977 in umbilical veins of 3/70 (4.3%) infants, all
unexposed to AZT. The amount of dmtDNA4977 out of the total
mitochondrial DNA was low and varied between 0.00094% and
0.014%. As there was no significant difference between AZT-
exposed and AZT-unexposed newborns (p = 0.55), we suggest that
our findings could be explained by the influence of external factors
other than AZT. It is well known that mitochondrial mutagenesis
depends on many different factors such as alcohol [38,50] or
nicotine [51]. While these stressors are known to damage
mitochondrial DNA there are also findings on protective factors,
e. g. green tea [52] or other dietary components. We did, however,
not investigate such possibly influencing factors. It is also
imaginable that the difference was not significant due to low
sample size. On the other hand, since none of the AZT-exposed
infants displayed the deletion, we cannot rule out the possibility
that AZT has a benefical impact with regard to the emergence of
the mtDNA4977.
Altogether, we did not find evidence for an increased risk
resulting from AZT for the most common mitochondrial deletion
in placenta or umbilical cord tissues of HIV-1 infected women and
their infants.
There is no doubt that AZT can cause mitochondrial toxicity.
However, the mitochondrial toxicity of AZT may be counter-
balanced by the positive effect of AZT on maternal HIV-1
infection. Compared to individuals under ARV long-term
treatment, the situation may be different in pregnant, drug-naive
women taking AZT for a short period only. Generally, HIV-
infection of the mother has a profound derogatory effect on the
cell-mediated immunity and T-cell maturation of the infant [53].
In HIV-positive individuals, the inflammatory cytokine tumor
necrosis factor alpha (TNF-alpha) is elevated [54–55] which also
applies to placental trophoblastic cells [56–57]. However, in-
creased TNF-alpha levels lead to mitochondrial DNA damage
including mtDNA depletion [58–60]. Interestingly, AZT has been
shown to down-regulate the expression of TNF-alpha in placental
tissue [61]; this mechanism could prevent HIV-induced mito-
chondrial damage and explain the higher mtDNA levels in
placenta and umbilical cord samples of AZT-exposed women and
infants as observed in our study.
Accordingly, it has been shown that mtDNA levels in PBMCs of
HIV-positive adults and infants increase after start of ARV
treatment. This finding has been interpreted by some authors as
restorative effect due to suppression of HIV-1 infection and by
others as over-replication to compensate for mitochondrial
dysfunction [21,44,62]. However, we believe that mtDNA over-
replication as a sign for mitochondrial dysfunction is unlikely in
our study, as it has been shown that antenatal AZT exposure leads
to decreased mtDNA levels but increased mitochondrial morpho-
logical damage in placenta and umbilical cords of fetal patas
monkeys [6,9].
There is a wide variety of factors influencing the mitochondrial
toxicity of NRTIs, like the type of NRTI (e.g. d4T or AZT), the
material to be analyzed (e.g PBMCs or tissues), mitochondrial
outcome parameter (e.g mtDNA or activities of mitochondrial
respiratory chain complexes) or stage of HIV-1 disease; this could
explain the somewhat ambiguous results of the studies conducted
so far.
There are also technical issues involved. Contamination with
platelets is one possible confounder of measuring mtDNA
Table 1. Demographic and clinical characteristics of HIV-1 infected women and their infants with or without AZT exposure during
pregnancy.
No antenatal AZT (n =53) Antenatal AZT (n =30)
Characteristics n % or median (IQR) n % or median (IQR) p-value
Duration of AZT intake, days 53 No intake 30 56 (43–70)
Maternal age, years 51 25 (23–29) 30 28 (25–30) 0.12
Maternal weight, kg 46 59 (55–68) 29 61 (56–65) 0.38
Education, years 45 7 (6–7) 26 7 (7–7) 0.26
Marital status, married 50 72 28 75 0.77
Gravidity 51 3 (2–3) 30 3 (2–3.3) 0.54
Parity 51 2 (1–2) 30 2 (1–2.3) 0.68
Maternal CD4 count at delivery, uL 36 307 (184–462) 19 402 (272–492) 0.10
Prematurity (,37 wk gestation) 51 3.9 30 13.3 0.19
Mode of delivery, caesarean section 49 6.1 30 6.7 1.0
Apgar score at 1 minute 41 9 (8–9) 29 9 (8.5–9) 0.08
Female sex of infant 50 58 30 40 0.12
Infant birth weight, g 48 3100 (2800–3300) 29 3200 (2950–3500) 0.30
Child length, cm 42 48 (46–50) 27 48 (46–50) 0.71
Child head circumference, cm 42 35 (34–36) 27 36 (34–36) 0.11
doi:10.1371/journal.pone.0041637.t001
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content in PBMCs by real-time PCR, as platelets are not
completely removed during standard Ficoll gradient separation
method [63–64]. In real time PCR, the mtDNA/nDNA-ratio is
calculated; as platelets do contain mtDNA, but not nDNA, every
increase of platelets leads automatically to a higher mtDNA/
nDNA-ratio resulting in higher calculated mtDNA levels.
Furthermore, other factors like human mitochondrial DNA
mutations and haplotypes may influence the development of HIV-
and NRTI-associated mitochondrial dysfunction [65–70]. There
are nine known European mitochondrial DNA haplotypes,
whereas the greatest and still insufficiently characterized variety
of mitochondrial haplotypes can be found in Africa; one study
revealed 105 haplotypes with 75 forming a single, unique African
haplogroup L [71]. Since we analyzed samples from Tanzanian
women, it cannot be excluded that other populations harboring
different mitochondrial DNA haplotypes react differently towards
AZT-exposure.
In conclusion, in our setting of relatively immunocompromized
drug-naive pregnant women from rural Tanzania, antenatal AZT
intake seemed to improve mitochondrial parameters in the women
and their infants.
Acknowledgments
We deeply thank all women who participated in this study with their
infants. The authors would like to express their gratitude to all staff of
Kyela District Hospital, the District Medical officer, the Regional Health
Management Team and the National AIDS Control Program in Tanzania.
Author Contributions
Conceived and designed the experiments: A. Kunz NWS JS PM JZ IL
GH. Performed the experiments: A. Kunz NWS JS JZ IL PM FD AH A.
Katerna. Analyzed the data: A. Kunz NWS ST GH. Contributed
reagents/materials/analysis tools: NWS JS GH FD GH. Wrote the paper:
A. Kunz NWS JS ST AH GH. Revision of manuscript draft: A. Kunz
NWS JS JZ IL PM ST AH FD A. Katerna GH.
Figure 1. Box/whisker plots of mitochondrial DNA levels in AZT-exposed and AZT-unexposed placenta and umbilical cords. Box and
whisker plots show mitochondrial DNA (mtDNA) levels in placentas of HIV-1 infected women and in umbilical cords of their infants according to
exposure to antenatal AZT. The median mtDNA level was significantly higher in women exposed to AZT compared to women without AZT-exposure.
Accordingly, the median mtDNA level was significantly higher in umbilical cords of infants exposed to AZT compared to infants without AZT-
exposure.
doi:10.1371/journal.pone.0041637.g001
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